Vivo Capital
EPRX icon

Vivo Capital’s Eupraxia Pharmaceuticals EPRX Stock Holding History

Vivo Capital’s Portfolio EPRX Stock Details EPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$12.3M Hold
1,350,000
– – 1.35% 26
2026
Q2 		$8.92M Hold
1,350,000
– – 0.81% 30
2026
Q1 		$9.8M Hold
1,350,000
– – 0.81% 32
2025
Q4 		$10.2M Hold
1,350,000
– – 0.66% 34
2025
Q3 		$7.96M Buy
+1,350,000
New +$7.35M 0.64% 35

Other funds holding EPRX

Beutel, Goodman & Co
Beutel, Goodman & Co Toronto, Ontario, Canada $12.7B AUM 12.76% 1-Year Est. Return
Affinity Asset Advisors
Affinity Asset Advisors New York $2.46B AUM 196.28% 1-Year Est. Return
Scotia Capital
Scotia Capital Toronto, Ontario, Canada $28.7B AUM 25.13% 1-Year Est. Return
Picton Mahoney Asset Management
Picton Mahoney Asset Management Toronto, Ontario, Canada $14.8B AUM 38.11% 1-Year Est. Return
Aisling Capital Management
Aisling Capital Management New York $299M AUM 39.78% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
CIBC World Market
CIBC World Market Toronto, Ontario, Canada $61.4B AUM 32.2% 1-Year Est. Return
F.L. Putnam Investment Management
F.L. Putnam Investment Management Lynnfield, Massachusetts $9.33B AUM 30.52% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $114B AUM 35.47% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return

Vivo Capital's EPRX Position: Q3 2026 in Review

Vivo Capital held its Eupraxia Pharmaceuticals (EPRX) position steady in Q3 2026 at 1,350,000 shares worth $12.3M. The position accounts for 1.35% of the portfolio, ranked #26.

Vivo Capital first reported a position in EPRX in Q3 2025 and has held it in 5 quarters since. 35 funds tracked by Wall St. Rank hold EPRX as of Q3 2026.

  • Vivo Capital held 1,350,000 shares of Eupraxia Pharmaceuticals worth $12.3M as of Q3 2026.
  • Vivo Capital left its Eupraxia Pharmaceuticals share count unchanged in Q3 2026.
  • Eupraxia Pharmaceuticals made up 1.35% of Vivo Capital's portfolio in Q3 2026, its #26 holding.
  • Vivo Capital first reported a position in Eupraxia Pharmaceuticals in Q3 2025 and has held it in 5 quarters since.
  • 35 funds tracked by Wall St. Rank held Eupraxia Pharmaceuticals as of Q3 2026.

Based on Vivo Capital's 13F filing for Q3 2026, filed 13 Nov 2026.